Amgen Company Profile (NASDAQ:AMGN)

About Amgen (NASDAQ:AMGN)

Amgen logoAmgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:AMGN
  • CUSIP: 03116210
  • Web:
  • Market Cap: $125.61352 billion
  • Outstanding Shares: 735,399,000
Average Prices:
  • 50 Day Moving Avg: $172.48
  • 200 Day Moving Avg: $166.30
  • 52 Week Range: $133.64 - $184.21
  • Trailing P/E Ratio: 16.58
  • Foreward P/E Ratio: 13.72
  • P/E Growth: 3.09
Sales & Book Value:
  • Annual Revenue: $22.93 billion
  • Price / Sales: 5.60
  • Book Value: $41.62 per share
  • Price / Book: 4.19
  • Annual Dividend: $4.60
  • Dividend Yield: 2.7%
  • EBIDTA: $12.1 billion
  • Net Margins: 35.46%
  • Return on Equity: 29.85%
  • Return on Assets: 11.72%
  • Debt-to-Equity Ratio: 1.06%
  • Current Ratio: 6.20%
  • Quick Ratio: 4.14%
  • Average Volume: 3.40 million shs.
  • Beta: 1.36
  • Short Ratio: 2.12
Frequently Asked Questions for Amgen (NASDAQ:AMGN)

What is Amgen's stock symbol?

Amgen trades on the NASDAQ under the ticker symbol "AMGN."

How often does Amgen pay dividends? What is the dividend yield for Amgen?

Amgen declared a quarterly dividend on Friday, July 28th. Investors of record on Thursday, August 17th will be given a dividend of $1.15 per share on Friday, September 8th. This represents a $4.60 dividend on an annualized basis and a yield of 2.64%. View Amgen's Dividend History.

How were Amgen's earnings last quarter?

Amgen Inc. (NASDAQ:AMGN) posted its quarterly earnings data on Tuesday, July, 25th. The company reported $3.27 earnings per share for the quarter, beating the Zacks' consensus estimate of $3.11 by $0.16. The company had revenue of $5.81 billion for the quarter, compared to analyst estimates of $5.67 billion. Amgen had a net margin of 35.46% and a return on equity of 29.85%. The company's quarterly revenue was up 2.1% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.84 earnings per share. View Amgen's Earnings History.

When will Amgen make its next earnings announcement?

Amgen is scheduled to release their next quarterly earnings announcement on Wednesday, October, 25th 2017. View Earnings Estimates for Amgen.

Where is Amgen's stock going? Where will Amgen's stock price be in 2017?

22 brokerages have issued 1-year price objectives for Amgen's stock. Their predictions range from $161.00 to $209.00. On average, they anticipate Amgen's stock price to reach $187.39 in the next twelve months. View Analyst Ratings for Amgen.

What are analysts saying about Amgen stock?

Here are some recent quotes from research analysts about Amgen stock:

  • 1. Cann analysts commented, "Amgen reported GAAP earnings per share of $2.91, which is 3.2% higher than our estimate of $2.83. Earnings exceeded our expectations due to higher than estimated product sales and a lower than estimated tax rate. Higher than estimated product sales were primarily driven by higher sales of Aranesp, Kyprolis, Blincyto, and Sensipar. Nearly all of Amgen’s products exceeded our estimates for International sales. Total product sales of $5.57 billion exceeded our estimated $5.47 billion by 1.8% and exceeded consensus product sales by 2.7%." (7/26/2017)
  • 2. Cowen and Company analysts commented, "Amgen reported Q1 Revenue of $5.46B (-1% Y/Y, vs. consensus of $5.61BE) and." (4/27/2017)
  • 3. BMO Capital Markets analysts commented, "We expect the overall survival (OS) benefit in relapsed myeloma patients to enable Kyprolis to grow in the face of generic competition for Velcade. Upside, however, is in our opinion dependent on data in combination with Revlimid+dex (ECOG Ph3) in newly-diagnosed patients given failure of CLARION. Anecdotal data suggests that Darzalex is best suited in IMiD and proteasome inhibitor failures given lack of response of these agents in patients failing Darzalex." (3/6/2017)
  • 4. According to Zacks Investment Research, "Amgen growth products – Prolia, Xgeva, Vectibix, Nplate and Sensipar – are performing well. Amgen’s restructuring plan should make it leaner and more cost efficient. Amgen is also progressing with its pipeline given quite a few regulatory and data updates scheduled for the coming quarters. Amgen has a positive record of earnings surprises in recent quarters. Amgen’s shares surpassed that of Biomed-Genetics industry in 2016. However, the company has some challenges in store given the presence of biosimilar competition and slowdown in sales of mature products. Biosimilars are starting to have a negative impact on key products like Neupogen and Neulasta in the EU. Moreover, minimal sales price increases and stiff competition can hurt blockbuster Enbrel sales in 2017. Estimates have also declined lately ahead of the company’s Q4 earnings release." (1/3/2017)

Who are some of Amgen's key competitors?

Who are Amgen's key executives?

Amgen's management team includes the folowing people:

  • Robert A. Bradway, Chairman of the Board, President, Chief Executive Officer
  • David W. Meline, Executive Vice President, Chief Financial Officer
  • Sean E. Harper, Executive Vice President - Research and Development
  • Anthony C. Hooper, Executive Vice President - Global Commercial Operations
  • Brian M. McNamee, Executive Vice President - Full Potential Initiatives
  • Esteban Santos, Executive Vice President, Operations
  • Cynthia M. Patton, Senior Vice President, Chief Compliance Officer
  • Jonathan P. Graham, Senior Vice President, General Counsel, Secretary
  • Lori A. Johnston, Senior Vice President
  • David A. Piacquad, Senior Vice President - Business Development

Who owns Amgen stock?

Amgen's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Bank of Montreal Can (0.37%), APG Asset Management N.V. (0.22%), Flossbach Von Storch AG (0.18%), NN Investment Partners Holdings N.V. (0.12%), Smead Capital Management Inc. (0.10%) and US Bancorp DE (0.10%). Company insiders that own Amgen stock include Annette Louise Such, Carbonnel Francois De, Cynthia M Patton, David Baltimore, Fred Hassan, Madhavan Balachandran and Sean E Harper. View Institutional Ownership Trends for Amgen.

Who sold Amgen stock? Who is selling Amgen stock?

Amgen's stock was sold by a variety of institutional investors in the last quarter, including APG Asset Management N.V., Assenagon Asset Management S.A., Bank of Montreal Can, NN Investment Partners Holdings N.V., ING Groep NV, Boston Advisors LLC, Douglas Lane & Associates LLC and Russell Investments Group Ltd.. Company insiders that have sold Amgen stock in the last year include Annette Louise Such and Cynthia M Patton. View Insider Buying and Selling for Amgen.

Who bought Amgen stock? Who is buying Amgen stock?

Amgen's stock was bought by a variety of institutional investors in the last quarter, including Harbour Capital Advisors LLC, First Quadrant L P CA, Mn Services Vermogensbeheer B.V., Flossbach Von Storch AG, Ferguson Wellman Capital Management Inc., Grimes & Company Inc., National Pension Service and Manning & Napier Advisors LLC. View Insider Buying and Selling for Amgen.

How do I buy Amgen stock?

Shares of Amgen can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Amgen's stock price today?

One share of Amgen stock can currently be purchased for approximately $174.54.

MarketBeat Community Rating for Amgen (NASDAQ AMGN)
Community Ranking:  3.1 out of 5 (  )
Outperform Votes:  932 (Vote Outperform)
Underperform Votes:  550 (Vote Underperform)
Total Votes:  1,482
MarketBeat's community ratings are surveys of what our community members think about Amgen and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Amgen (NASDAQ:AMGN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 11 Hold Ratings, 10 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 2.55)
Consensus Price Target: $187.39 (7.36% upside)

Analysts' Ratings History for Amgen (NASDAQ:AMGN)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/27/2017ArgusBoost Price TargetBuy$180.00 -> $195.00LowView Rating Details
7/26/2017Oppenheimer Holdings, Inc.Reiterated RatingOutperform$189.00 -> $203.00LowView Rating Details
7/26/2017Deutsche Bank AGReiterated RatingHold$172.00 -> $174.00LowView Rating Details
7/26/2017BMO Capital MarketsDowngradeOutperform -> Market PerformLowView Rating Details
7/26/2017CannReiterated RatingBuy$189.00 -> $203.00LowView Rating Details
7/22/2017Cowen and CompanyReiterated RatingOutperform$209.00LowView Rating Details
7/17/2017Jefferies Group LLCReiterated RatingBuy$195.00LowView Rating Details
7/14/2017Credit Suisse GroupSet Price TargetHold$177.00LowView Rating Details
7/10/2017Morgan StanleyReiterated RatingOverweightLowView Rating Details
7/9/2017MizuhoReiterated RatingBuy$195.00LowView Rating Details
6/26/2017William BlairReiterated RatingMarket PerformLowView Rating Details
6/22/2017Leerink SwannReiterated RatingMarket Perform$161.00LowView Rating Details
6/8/2017Sanford C. BernsteinSet Price TargetHold$164.00MediumView Rating Details
4/28/2017Robert W. BairdReiterated RatingNeutral$165.00LowView Rating Details
3/20/2017Goldman Sachs Group, Inc. (The)Lower Price TargetConviction-Buy$208.00 -> $202.00LowView Rating Details
3/14/2017Piper Jaffray CompaniesReiterated RatingOverweight$193.00LowView Rating Details
1/31/2017Royal Bank Of CanadaSet Price TargetBuy$190.00N/AView Rating Details
2/1/2017Bank of America CorporationUpgradeNeutral -> Buy$156.68 -> $192.00N/AView Rating Details
12/13/2016Chardan CapitalUpgradeSell -> NeutralN/AView Rating Details
9/28/2016Citigroup Inc.Lower Price TargetNeutral$175.00 -> $172.00N/AView Rating Details
9/28/2016J P Morgan Chase & CoReiterated RatingHoldN/AView Rating Details
8/26/2016GabelliInitiated CoverageHoldN/AView Rating Details
7/28/2016Barclays PLCReiterated RatingEqual Weight$185.00N/AView Rating Details
2/23/2016BTIG ResearchReiterated RatingSell$135.00N/AView Rating Details
1/22/2016Wells Fargo & CompanyReiterated RatingHoldN/AView Rating Details
12/18/2015Atlantic SecuritiesInitiated CoverageOverweight$202.00N/AView Rating Details
9/22/2015NomuraReiterated RatingBuy$190.00 -> $191.00N/AView Rating Details
8/31/2015Raymond James Financial, Inc.Initiated CoverageMarket PerformN/AView Rating Details
(Data available from 7/29/2015 forward)


Earnings History for Amgen (NASDAQ:AMGN)
Earnings by Quarter for Amgen (NASDAQ:AMGN)
Earnings History by Quarter for Amgen (NASDAQ AMGN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/25/2017$3.11N/AView Earnings Details
7/25/2017Q2 2017$3.11$3.27$5.67 billion$5.81 billionViewN/AView Earnings Details
4/26/2017Q1 2017$3.00$3.15$5.60 billion$5.46 billionViewN/AView Earnings Details
2/2/2017Q416$2.79$2.89$5.75 billion$5.97 billionViewListenView Earnings Details
10/27/2016Q316$2.79$3.02$5.73 billion$5.81 billionViewListenView Earnings Details
7/27/2016Q216$2.74$2.84$5.58 billion$5.69 billionViewListenView Earnings Details
4/28/2016Q116$2.60$2.90$5.32 billion$5.53 billionViewListenView Earnings Details
1/28/2016Q415$2.29$2.61$5.53 billion$5.54 billionViewListenView Earnings Details
10/28/2015Q315$2.38$2.72$5.32 billion$5.72 billionViewListenView Earnings Details
7/30/2015Q215$2.43$2.57$5.32 billion$5.37 billionViewListenView Earnings Details
4/21/2015Q115$2.07$2.48$4.91 billion$5.03 billionViewListenView Earnings Details
1/27/2015Q414$2.05$2.16$5.20 billion$5.33 billionViewListenView Earnings Details
10/27/2014Q314$2.11$2.30$4.95 billion$5.03 billionViewListenView Earnings Details
7/29/2014Q214$2.07$2.37$4.90 billion$5.18 billionViewListenView Earnings Details
4/22/2014Q114$1.94$1.87$4.76 billion$4.52 billionViewListenView Earnings Details
1/28/2014Q413$1.69$1.82$4.81 billion$5.01 billionViewListenView Earnings Details
10/22/2013Q313$1.78$1.94$4.60 billion$4.75 billionViewListenView Earnings Details
7/30/2013Q2 2013$1.74$1.89$4.49 billion$4.68 billionViewListenView Earnings Details
4/23/2013Q1 2013$1.84$1.96$4.37 billion$4.24 billionViewN/AView Earnings Details
1/23/2013Q4 2012$1.42$1.40$4.37 billion$4.42 billionViewListenView Earnings Details
10/23/2012$1.47$1.67ViewN/AView Earnings Details
7/26/2012$1.54$1.83ViewN/AView Earnings Details
1/26/2012$1.22$1.21ViewN/AView Earnings Details
10/24/2011$1.29$1.40ViewN/AView Earnings Details
7/29/2011$1.29$1.37ViewN/AView Earnings Details
4/20/2011$1.29$1.34ViewN/AView Earnings Details
1/24/2011$1.11$1.17ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Amgen (NASDAQ:AMGN)
2017 EPS Consensus Estimate: $12.28
2018 EPS Consensus Estimate: $12.67
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$3.04$3.17$3.09
Q2 20173$3.05$3.12$3.09
Q3 20173$3.01$3.17$3.11
Q4 20173$2.97$2.99$2.98
Q1 20181$3.29$3.29$3.29
Q2 20181$3.18$3.18$3.18
Q3 20181$3.10$3.10$3.10
Q4 20181$3.10$3.10$3.10
(Data provided by Zacks Investment Research)


Current Dividend Information for Amgen (NASDAQ:AMGN)
Next Dividend:9/8/2017
Annual Dividend:$4.60
Dividend Yield:2.64%
Dividend Growth:28.60% (3 Year Average)
Payout Ratio:41.93% (Trailing 12 Months of Earnings)
36.77% (Based on This Year's Estimates)
36.16% (Based on Next Year's Estimates)
Track Record:6 Years of Consecutive Dividend Growth
Dividend Payments by Quarter for Amgen (NASDAQ:AMGN)

Dividend History by Quarter for Amgen (NASDAQ AMGN)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Amgen (NASDAQ:AMGN)
Insider Ownership Percentage: 0.20%
Institutional Ownership Percentage: 78.87%
Insider Trades by Quarter for Amgen (NASDAQ:AMGN)
Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)
Insider Trades by Quarter for Amgen (NASDAQ:AMGN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/24/2017Cynthia M PattonSVPSell2,922$154.40$451,156.80View SEC Filing  
8/2/2016Annette Louise SuchVPSell3,000$174.59$523,770.00View SEC Filing  
5/4/2016Madhavan BalachandranEVPSell30,000$154.12$4,623,600.00View SEC Filing  
4/29/2016David BaltimoreDirectorSell3,312$157.21$520,679.52View SEC Filing  
4/29/2016Sean E HarperEVPSell21,875$157.99$3,456,031.25View SEC Filing  
8/31/2015Carbonnel Francois DeDirectorSell5,000$153.84$769,200.00View SEC Filing  
8/19/2015Fred HassanDirectorBuy3,010$166.63$501,556.30View SEC Filing  
6/2/2015Cynthia M PattonSVPSell4,530$157.06$711,481.80View SEC Filing  
4/23/2015Stuart A TrossSVPSell3,012$169.31$509,961.72View SEC Filing  
4/22/2015Sean E HarperEVPSell28,000$171.58$4,804,240.00View SEC Filing  
3/3/2015Stuart A TrossSVPSell4,415$157.74$696,422.10View SEC Filing  
3/2/2015David BaltimoreDirectorSell3,647$158.76$578,997.72View SEC Filing  
2/11/2015Robert A BradwayCEOSell22,000$152.69$3,359,180.00View SEC Filing  
2/5/2015Frank C HerringerDirectorBuy3,000$152.29$456,870.00View SEC Filing  
12/3/2014Carbonnel Francois DeDirectorSell3,000$168.01$504,030.00View SEC Filing  
8/5/2014Cynthia M PattonSVPSell2,644$127.97$338,352.68View SEC Filing  
8/5/2014Sean E HarperEVPSell14,000$127.29$1,782,060.00View SEC Filing  
5/21/2014Thomas J.W. DittrichCAOSell4,130$112.83$465,987.90View SEC Filing  
4/28/2014A Kelly MichaelCFOSell2,065$110.45$228,079.25View SEC Filing  
3/6/2014Carbonnel Francois DeDirectorSell1,000$126.69$126,690.00View SEC Filing  
9/4/2013Madhavan BalachandranEVPSell18,000$112.76$2,029,680.00View SEC Filing  
8/28/2013David BaltimoreDirectorSell4,582$109.66$502,462.12View SEC Filing  
5/22/2013Thomas J.W. DittrichCAOSell6,130$104.78$642,301.40View SEC Filing  
5/21/2013Madhavan BalachandranEVPSell6,000$103.28$619,680.00View SEC Filing  
5/17/2013Rebecca M HendersonDirectorSell8,421$105.72$890,268.12View SEC Filing  
5/16/2013Cynthia M PattonSVPSell3,544$105.01$372,155.44View SEC Filing  
5/14/2013Judith C PelhamDirectorSell25,000$108.25$2,706,250.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Amgen (NASDAQ:AMGN)
Latest Headlines for Amgen (NASDAQ:AMGN)
DateHeadline logoAmgen: Income On Sale - Seeking Alpha - July 28 at 9:59 PM logoAmgen Inc. (AMGN) Announces $1.15 Quarterly Dividend - July 28 at 5:46 PM logoAmgen, Inc. :AMGN-US: Earnings Analysis: Q2, 2017 By the Numbers : July 28, 2017 - July 28 at 4:54 PM logoCourt Ruling on 'Biosimilars' Sets Stage for More Drug Acquisitions - July 28 at 4:54 PM logoAmgen Announces 2017 Third Quarter Dividend - July 28 at 4:54 PM logoAmgen Inc. (AMGN) Expected to Post Q4 2017 Earnings of $2.97 Per Share - July 28 at 4:11 PM logoFY2017 Earnings Estimate for Amgen Inc. (NASDAQ:AMGN) Issued By Gabelli - July 28 at 12:57 PM logoQ3 2017 EPS Estimates for Amgen Inc. (NASDAQ:AMGN) Boosted by Jefferies Group - July 28 at 8:15 AM logoAmgen gets fast US FDA review for adding heart benefits to cholesterol drug label - Nasdaq - July 27 at 8:31 PM logoFDA Grants Priority Review For Amgen's Supplemental Biologics License Application For Repatha® (evolocumab) To Include Data On Reducing Risk Of Cardiovascular Events - July 27 at 8:31 PM logoAmgen gets fast U.S. FDA review for adding heart benefits to cholesterol drug label - July 27 at 8:31 PM logoAMGN Named A Top Socially Responsible Dividend Stock - Nasdaq - July 27 at 3:30 PM logoAmgen Reports Q2: Short- And Long-Term Considerations - Amgen ... - Seeking Alpha - July 27 at 3:30 PM logoJefferies Group Analysts Boost Earnings Estimates for Amgen Inc. (AMGN) - July 27 at 10:43 AM logoLeerink Swann Weighs in on Amgen Inc.'s Q3 2017 Earnings (AMGN) - July 27 at 9:49 AM logoAmgen Inc. (NASDAQ:AMGN) Forecasted to Earn Q3 2017 Earnings of $3.01 Per Share - July 27 at 9:49 AM logoAmgen Inc. Reports 12% Gain In Q2 Bottom Line - Nasdaq - July 26 at 9:21 PM logo'Poor Quality' Amgen Earnings Beat Doesn't Impress These Two Wall Street Analysts - Benzinga - July 26 at 9:21 PM logo'Poor Quality' Amgen Earnings Beat Doesn't Impress These Two Wall Street Analysts - July 26 at 9:21 PM logoAmgen Inc. (NASDAQ:AMGN) Given New $185.00 Price Target at UBS AG - July 26 at 7:26 PM logoShort Sellers Run for Cover From Major Biotech Stocks - 24/7 Wall St. - July 26 at 4:20 PM logoAmgen (AMGN) Stock Falls Despite Q2 Earnings & Sales Beat - Nasdaq - July 26 at 4:20 PM logoAmgen, Inc. (AMGN) Stock Is a Trade for Ailing Portfolios - - July 26 at 4:20 PM logoUS STOCKS-Boeing, AT&T power Wall St to record; Fed in focus - July 26 at 4:20 PM logoUS STOCKS-Strong earnings power Wall St to record; Fed awaited - July 26 at 4:20 PM logoAmgen turned in a strong second quarter — but analysts say things are looking bleak - July 26 at 4:19 PM logoGains for AT&T and Boeing help lift US stock indexes higher - July 26 at 4:19 PM logoAmgen: It's Never Just About the Earnings - July 26 at 4:19 PM logoEdited Transcript of AMGN earnings conference call or presentation 25-Jul-17 9:00pm GMT - July 26 at 4:19 PM logoAmgen Inc. (NASDAQ:AMGN) Given Outperform Rating at Oppenheimer Holdings, Inc. - July 26 at 2:03 PM logoAmgen's (AMGN) Hold Rating Reiterated at Deutsche Bank AG - July 26 at 12:41 PM logoAmgen shares drop as earnings report reveals ‘embarrassingly bare’ drug pipeline - July 26 at 11:47 AM logoAmgen, Inc. (AMGN) Stock Is a Trade for Ailing Portfolios - July 26 at 10:33 AM logoAmgen Inc. (AMGN) Is Pulling Back After Q2 Report - July 26 at 1:44 AM logoAmgen second-quarter profit tops Street view, shares fall - July 26 at 1:44 AM logoAmgen (AMGN) Q2 2017 Results - Earnings Call Transcript - July 26 at 1:43 AM logoAmgen Reports Second Quarter 2017 Financial Results - July 26 at 1:43 AM logoAmgen beats on top line - July 26 at 1:43 AM logoAmgen 2nd quarter profit tops Street estimates, raises forecast - July 26 at 1:43 AM logoAmgen shares down 3% after company's guidance on lower end of expectations - July 26 at 1:43 AM logoAmgen beats Street 2Q forecasts - July 26 at 1:43 AM logoAmgen Inc. (AMGN) Announces Quarterly Earnings Results, Beats Estimates By $0.16 EPS - July 25 at 9:48 PM logoAmgen shares down 3% after company's guidance on lower end of expectations - MarketWatch - July 25 at 8:40 PM logoEarnings Reaction History: Amgen Inc., 54.5% Follow-Through Indicator, 3.1% Sensitive - Nasdaq - July 25 at 3:39 PM logoAmgen And Novartis: First Mover Advantage Is A Must - Seeking Alpha - July 25 at 4:27 AM logoShrinking dollar could boost the market and make these stocks big winners - July 24 at 6:23 PM logoAmgen Inc. (NASDAQ:AMGN) Rating Reiterated by Cowen and Company - July 22 at 2:08 PM logoAmgen Inc. (AMGN) Receives "Buy" Rating from BMO Capital Markets - July 22 at 11:42 AM logoAmgen Inc. (AMGN) Given Consensus Recommendation of "Buy" by Brokerages - July 22 at 12:28 AM logoAmgen (AMGN) to Report Q2 Earnings: What's in the Cards? - Nasdaq - July 21 at 10:31 PM



Amgen (AMGN) Chart for Saturday, July, 29, 2017

This page was last updated on 7/29/2017 by Staff